DENVER--(BUSINESS WIRE)--Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that an abstract describing the effects of darusentan on resistant hypertension has been selected for oral presentation at the American Heart Association Scientific Sessions conference to be held Nov. 12-15, 2006, at the McCormick Place Convention Center in Chicago, Ill.
